Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has Schrödinger's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SDGR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SDGR's weekly volatility (6%) has been stable over the past year.
7 Day Return
US Healthcare Services
1 Year Return
US Healthcare Services
Return vs Industry: SDGR underperformed the US Healthcare Services industry which returned 11.8% over the past year.
Return vs Market: SDGR underperformed the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Schrödinger's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHow Many Schrödinger, Inc. (NASDAQ:SDGR) Shares Have Insiders Sold, In The Last Year?
1 month ago | Simply Wall StEstimating The Intrinsic Value Of Schrödinger, Inc. (NASDAQ:SDGR)
1 month ago | Simply Wall StWhen Will Schrödinger, Inc. (NASDAQ:SDGR) Turn A Profit?
Is Schrödinger undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SDGR ($67.67) is trading below our estimate of fair value ($75.77)
Significantly Below Fair Value: SDGR is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: SDGR is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.
PE vs Market: SDGR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SDGR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SDGR is overvalued based on its PB Ratio (7.5x) compared to the US Healthcare Services industry average (6.4x).
How is Schrödinger forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SDGR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: SDGR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SDGR's is expected to become profitable in the next 3 years.
Revenue vs Market: SDGR's revenue (35.1% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: SDGR's revenue (35.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SDGR's Return on Equity is forecast to be low in 3 years time (4.5%).
How has Schrödinger performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SDGR is currently unprofitable.
Growing Profit Margin: SDGR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SDGR is unprofitable, but has reduced losses over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare SDGR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SDGR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (28.5%).
Return on Equity
High ROE: SDGR has a negative Return on Equity (-2.04%), as it is currently unprofitable.
How is Schrödinger's financial position?
Financial Position Analysis
Short Term Liabilities: SDGR's short term assets ($675.2M) exceed its short term liabilities ($67.6M).
Long Term Liabilities: SDGR's short term assets ($675.2M) exceed its long term liabilities ($44.8M).
Debt to Equity History and Analysis
Debt Level: SDGR is debt free.
Reducing Debt: SDGR has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SDGR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SDGR is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 27.2% per year.
What is Schrödinger current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SDGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SDGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SDGR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SDGR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SDGR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ramy Farid (57 yo)
Dr. Ramy Farid, Ph.D., serves as the President of Schrödinger, LLC since January 2008 and has been its Chief Executive Officer since January 2, 2017. Dr. Farid served as Director of Morphic Holding, Inc. f...
CEO Compensation Analysis
Compensation vs Market: Ramy's total compensation ($USD8.51M) is above average for companies of similar size in the US market ($USD5.31M).
Compensation vs Earnings: Ramy's compensation has increased whilst the company is unprofitable.
Experienced Management: SDGR's management team is considered experienced (4.4 years average tenure).
Experienced Board: SDGR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.
Schrödinger, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Schrödinger, Inc.
- Ticker: SDGR
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$4.771b
- Shares outstanding: 70.51m
- Website: https://www.schrodinger.com
Number of Employees
- Schrödinger, Inc.
- 120 West 45th Street
- 17th Floor
- New York
- New York
- United States
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/31 05:44|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.